![](/img/cover-not-exists.png)
HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin
Rugo, H., Barve, A., Waller, C., Bronchud, M.H., Herson, J., Yuan, J., Manikhas, A., Bondarenko, I., Mukhametshina, G., Nemsadze, G., Parra, J., Abesamis Tiambeng, M.L., Baramidze, K., Akewanlop, C.,Volume:
72
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(17)30216-2
Date:
February, 2017
File:
PDF, 54 KB
english, 2017